Why We’re In a ‘Golden Age’ of Life Sciences ...

Goldman Sachs President John Waldron speaks with Steven Tananbaum, CIO of GoldenTree Asset Management, about how GoldenTree became a credit-focused asset manager overseeing $70 billion. They discuss how credit markets have evolved during Tananbaum’s career, his framework for anal ...  Show more

Credit markets are playing a growing role in the buildout of artificial intelligence, with nearly $500 billion of AI-related debt issuance so far in 2026, according to estimates from Goldman Sachs Research. Amanda Lynam, head of credit strategy research, and Zach Ablon, head of t ...  Show more

The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller ...  Show more

In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ...  Show more

For all the exciting developments in the synthetic biology industry, there are also concerns. People can edit genes in their garages these days, so who’s regulating this space?Plus - we’ll hear about the exciting new business models with biology at their core, including one of th ...  Show more

In this week’s series focusing on business and science, we start things off by looking at the world of synthetic biology.The industry is estimated to be worth around $30bn in the next few years, but how is that money actually made?We speak to businesses across the world to find o ...  Show more